enVVeno Medical (NVNO) Q3 2026 Update: Narrower Loss and Steady Cash Runway

Key Takeaways

• enVVeno Medical reported a third-quarter 2026 net loss of $4.4 million, or $6.29 per share, compared with a net loss of $4.5 million, or $7.89 per share, in the same period last year.
• Total operating expenses came in at $4.5 million, down from $4.9 million a year earlier, even as the company prepared to launch its pivotal clinical study.
• The company ended the quarter with $18.5 million in cash and investments and reiterated that its resources are expected to fund operations into the fourth quarter of 2027.
• Quarterly cash burn was approximately $3 million, and management expects the burn rate to rise to between $4 million and $5 million per quarter in the first half of 2027 as patient enrollment accelerates.
• enVVeno remains a pre-revenue, clinical-stage company, making its regulatory and clinical milestones the primary drivers of shareholder value rather than top-line results.

Why Quarterly Results Matter for NVNO

For a clinical-stage medical device company like NVNO, earnings reports focus less on revenue and more on cash runway, expense control, and progress toward key regulatory steps. The company is developing the enVVe System, a first-in-class, non-surgical replacement venous valve for patients with severe deep chronic venous insufficiency (CVI), a condition affecting roughly 3 million people in the U.S. After receiving an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) earlier in 2026, enVVeno is preparing to enroll its first patients in the TAVVE pivotal study. This quarter’s update is worth reviewing because it shows whether the company has the capital and operational footing to move a potentially important therapy forward. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Breaking Down the Reported Numbers

enVVeno Medical reported a net loss of $4.4 million for the third quarter ended September 30, 2026, or $6.29 per basic and diluted share. That compares with a net loss of $4.5 million, or $7.89 per share, in the third quarter of 2025. The company remains pre-revenue, so there were no product sales. Total operating expenses totaled $4.5 million, down from $4.9 million in the prior-year quarter, which points to disciplined cost management while the team readied the TAVVE study. Cash burn for the quarter was about $3 million. As of September 30, 2026, enVVeno held roughly $18.5 million in cash and investments, including $2.6 million in cash and cash equivalents plus $15.9 million in short-term investments. Management noted that these resources should support operations into the fourth quarter of 2027.

Market Reaction and Investor Focus

Investor attention around the earnings has stayed on the company’s path toward starting patient enrollment in the TAVVE pivotal study rather than the income statement itself. Management indicated that clinical sites are being activated and that the first patient enrollment remains on track before year-end. This milestone, along with an earlier analyst upgrade and a $30 price target from Ladenburg, keeps sentiment centered on execution rather than near-term profits. Because NVNO is still pre-revenue, any delays in study timelines or unexpected capital needs could pressure the stock, while successful early enrollment could support confidence in the enVVe System’s potential. From what I see, the market is pricing in these clinical steps more than quarterly financial details.

Forward Outlook and Factors to Watch

The nearest catalyst is the start of Part 1 of the TAVVE pivotal study, expected to enroll up to 10 patients whose 30-day safety data will go to the FDA. After that review, the company plans to advance into Part 2, a randomized stage with 220 patients — 165 receiving the enVVe System and 55 in a control arm. Investors should track the pace of site activation and enrollment, since delays could stretch timelines and affect the cash position. Management expects quarterly cash burn to move to between $4 million and $5 million in the first half of 2027 as the study advances. Longer term, the goal is to submit a premarket approval (PMA) application to the FDA after 12-month follow-up on the randomized stage. Key items to monitor include operating expense trends, any financing activity, and early safety and efficacy data. These steps carry real clinical and regulatory risk, and there is no assurance the enVVe System will receive FDA approval. I’m watching this closely as the study gets underway.

Using Tickeron’s AI Tools in My Research

When I evaluate clinical-stage names like this, I find it helpful to run additional screens for context on sector trends and comparable companies. Tickeron’s AI Screener lets me quickly filter for relevant healthcare stocks and technical signals, which adds another layer to the fundamental review without replacing it. The platform’s customizable options for industry, market cap, and performance metrics make it straightforward to spot patterns across the space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume